Rigel Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Rigel Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Rigel Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Rigel Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Rigel Pharmaceuticals Inc (Rigel) is a biotechnology company. It focuses on discovering, developing and providing therapies for the treatment of hematologic disorders and cancer. Its major products include Tavalisse, an oral spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia, Rezlidhia for relapsed or refractory acute myeloid leukemia with IDH1 mutations, and Gavreto for metastatic RET fusion-positive non-small cell lung cancer and advanced thyroid cancers. Veppanu for the treatment of adults with estrogen receptoRigel collaborates with partners such as Novo Nordisk, Blueprint Medicines Corporation, and Eli Lilly and Company for research, development, and commercialization efforts. The company has an operational presence in the US, Europe, the UK, Canada, Israel, and Japan. Rigel is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
Suite 900, 611 Gateway Boulevard, South San Francisco, California, 94080
Website
www.rigel.com
Telephone
1 650 6241100
No of Employees
172
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RIGL (NASD)
Revenue (2024)
$294.3M
64.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
1999.1%
(2024 vs 2023)
Market Cap*
$877.2M
Net Profit Margin (2024)
XYZ
1,179.2%
(2024 vs 2023)
* As of and is in US$
Rigel Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Tavalisse Tablets: Chronic Immune Thrombocytopenia (ITP) | Tavalisse |
| Rezlidhia Capsules: Acute Myeloid Leukemia (AML) | Rezlidhia |
| Gavreto: Non-Small Cell Lung Cancer (NSCLC) | Gavreto |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In January, the company received orphan drug designation from the US Food and Drug Administration (FDA) to R289 for the treatment of myelodysplastic syndromes (MDS). |
| 2024 | Regulatory Approval | In December, the company received Fast Track designation from the US FDA for R289, for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). |
| 2024 | Contracts/Agreements | In October, the company expanded its agreement with Kissei to include REZLIDHIA (olutasidenib) in Japan, the Republic of Korea and Taiwan, to develop and commercialize olutasidenib. |
Competitor Comparison
| Key Parameters | Rigel Pharmaceuticals Inc | Amgen Inc | Teva Pharmaceutical Industries Ltd | BioCryst Pharmaceuticals Inc | Dova Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Israel | United States of America | United States of America |
| City | South San Francisco | Thousand Oaks | Tel Aviv | Durham | Durham |
| State/Province | California | California | Tel Aviv | North Carolina | North Carolina |
| No. of Employees | 172 | 31,500 | 31,173 | 435 | 115 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gregg A. Lapointe | Chairman | Executive Board | 2017 | 67 |
| Raul R. Rodriguez | Director; President; Chief Executive Officer | Executive Board | 2014 | 65 |
| Dean L. Schorno | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | 63 |
| Raymond J. Furey | General Counsel; Secretary; Chief Compliance Officer; Executive Vice President | Senior Management | 2023 | 58 |
| David A. Santos | Executive Vice President; Chief Commercial Officer | Senior Management | 2020 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer